Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals (Detail) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2023		Dec. 31, 2022		Dec. 31, 2021
Restructuring Reserve [Roll Forward]
Beginning balance		$ 1,204	[1]	$ 1,071
Provision	[2]	1,968		882		$ 741
Utilization and other	[3]	(1,184)		(750)
Ending balance		1,988	[4]	1,204	[1]	1,071
Employee Termination Costs [Member]
Restructuring Reserve [Roll Forward]
Beginning balance		1,196	[1]	1,014
Provision		1,622		776
Utilization and other	[3]	(840)		(594)
Ending balance		1,978	[4]	1,196	[1]	1,014
Asset Impairment Charges [Member]
Restructuring Reserve [Roll Forward]
Beginning balance		0	[1]	0
Provision		227		52
Utilization and other	[3]	(227)		(52)
Ending balance		0	[4]	0	[1]	0
Exit Costs [Member]
Restructuring Reserve [Roll Forward]
Beginning balance		8	[1]	57
Provision		119		54
Utilization and other	[3]	(116)		(103)
Ending balance		$ 11	[4]	$ 8	[1]	$ 57

[1] Included in Other current liabilities ($991 million) and Other noncurrent liabilities ($213 million).

[2] Primarily represents cost-reduction initiatives. Amounts associated with our Biopharma segment: $672 million for 2023 (including charges of $665 million for Realigning our Cost Base Program and credits of $20 million for Transforming to a More Focused Company program), $354 million for 2022 (including charges of $291 million for Transforming to a More Focused Company program) and $610 million for 2021 (including charges of $612 million for Transforming to a More Focused Company program).

[3] includes adjustments for foreign currency translation that are not material to our consolidated financial statements.

[4] Included in Other current liabilities ($1.3 billion) and Other noncurrent liabilities ($663 million).